Introduction {#s1}
============

Acute myeloid leukemia (AML) is a heterogeneous group of diseases with variable response to therapy, due to intrinsic genetic complexity, present at diagnosis, and/or developing during disease evolution ([@B1], [@B2]). For these reasons, characterization of molecular and phenotypic AML profiles is essential at the time of initial presentation, with the objective to design patient- and disease-specific strategies aimed to prevent disease relapse and improve long-term outcome.

Current prognostic assessment of AML depends on several factors ([@B3], [@B4]). Cytogenetics and mutational profile allow to stratify AML into prognostic subgroups associated with significantly different complete remission (CR), relapse and overall survival (OS) rates ([@B5]); thus, genetic characteristics of leukemic cells are increasingly used to guide treatment approaches ([@B3], [@B6]). In 2010, the European LeukemiaNet (ELN) defined the first genetic-based stratification system for AML and recently published a revised version, refining the definition of three prognostic subgroups (favorable, intermediate, adverse), rather than the previous four groups ([@B6], [@B7]) ([Figure 1](#F1){ref-type="fig"}). Among major changes made in the revised system is the quantification of *FLT3*-ITD allelic burden, defined by the ITD allelic ratio (AR), which has been associated to the risk of relapse ([@B8]). In this context, *NPM1*-mutated AML with *FLT3*-ITD AR \< 0.5 (*FLT3*-ITD*low*) are classified as prognostically favorable, similar to *NPM1*-mutated/*FLT3* wild-type AML ([@B6]). Notably, this is the first time that *FLT3*-ITD mutated AML are classified as "favorable" ([@B9]). By contrast, *NPM1* wild-type AML with *FLT3*-ITD AR \>0.5 (*FLT3*-ITD*high*) are classified as "adverse-risk," while AML *NPM1*-mutated/*FLT3*-ITD*high* are considered "intermediate-risk" ([@B6]) ([Figure 1](#F1){ref-type="fig"}).

![ELN-2017 risk stratification of AML by genetic abnormalities \[Adapted from Dohner et al. ([@B6])\].](fonc-09-00655-g0001){#F1}

Prognostic assessment of AML at diagnosis has strong clinical relevance, allowing for instance to allocate patients with high-risk disease to receive allogeneic stem cell transplantation (allo-SCT) in first remission as part of frontline therapy ([@B10], [@B11]), while patients with favorable-risk AML would not be candidates to allo-SCT ([@B6]). Conversely, the indication for allo-SCT in first complete remission for the large subset of patients with intermediate-risk disease is currently a matter of debate ([@B12]). These figures may further change in the near future due to the incorporation of targeted treatments added to conventional chemotherapy, as the recently approved FLT3 inhibitors midostaurin or quizartinib ([@B13], [@B14]), which may change risk-stratification according to *FLT3* mutation status.

Recent technological advances have contributed to increase the list of AML mutations associated to adverse prognosis. In particular, in the past decade, the advent of Next Generation Sequencing (NGS) technologies led to the identification of novel molecular abnormalities that shed new light into the pathogenesis and prognosis of the disease, and have been therefore, incorporated in the revised ELN guidelines ([@B6], [@B15], [@B16]).

Despite improved genetic classification and CR rates close to \~80%, more than 50% of adult patients with AML will undergo disease relapse after initial treatment ([@B12], [@B17]), due to the emergence of resistant clones surviving therapy ([@B18]). In fact, although an accurate quantification of blasts may be provided by optical microscopy when declaring morphological CR (mCR), a relevant amount of residual leukemic cells, estimated to range from 10^10^ to 10^12^ may still persist in a normal adult ([@B19]). A precise estimate of residual disease below the threshold of mCR represents a critical issue in prognostic assessment and in the post-remission decision-making process in AML. This is the purpose of techniques aiming at minimal residual disease (MRD) detection ([@B20]). However, since the capability to detect leukemic cells depends on the methodology used, the term "measurable" residual disease has been recently proposed to indicate the levels of leukemic cells detectable by modern technologies, which are characterized by very high sensitivity ([@B19]). The advantage of identifying by molecular methods MRD levels predictive of clinical relapse has been proven for acute promyelocytic leukemia (APL), where a positive *PML-RARA* test after the end of consolidation therapy is invariably associated to overt relapse ([@B21]). As a consequence, pre-emptive treatment of molecular relapse is currently recommended as standard practice in APL and is being now considered in some specific non-APL AML subsets ([@B22]).

In this context, the updated ELN recommendations introduced the concept of MRD-negative mCR as a new outcome definition ([@B6]), in cases where a given genetic or immunophenotypic aberration present at diagnosis is no longer detectable by high sensitivity multiparametric flow-cytometry (MFC), or reverse transcriptase-quantitative PCR (RT-qPCR) ([@B6], [@B23]). Following the definition of this new outcome, the AML ELN MRD working group felt the need for the first consensus document on MRD standardization/harmonization in AML ([@B24]). According to the panel, MRD measurement provides an objective methodology to establish a deeper remission status in AML treatment, whatever the method employed. The ELN consensus suggests that efforts should be directed to assign to individual patients a reliable tool to monitor MRD and estimate the risk of relapse. More specifically, AML subgroups including APL, core binding factor (CBF) AML, and *NPM1*-mutated AML should be monitored by RT-qPCR, whereas the use of MFC is strongly recommended in all other AML subgroups ([@B23], [@B24]).

In this review, we will focus on recent methodological and conceptual advances in the field of MRD assessment in AML, and their inclusion in the decision-making process of personalized treatment.

RT-qPCR {#s2}
=======

In AML, molecular MRD monitoring includes quantification of *PML-RARA* *(*[@B25], [@B26]*), RUNX1-RUNX1T1* *(*[@B27]*), CBFB-MYH11* *(*[@B28]*)*, and mutated-*NPM1* ([@B29], [@B30]). RT-qPCR methods for the above fusion genes have been standardized by the Europe Against Cancer (EAC) consortium, and are widely used by hematology laboratories worldwide ([@B31]). The advantages of RT-qPCR over nested-PCR include high specificity and sensitivity for leukemic cells, decreased contamination risk, better evaluation of the quality of RNA, and potential to assess the kinetics of MRD longitudinally. As a consequence, this approach has had wide application in routine patients\' care. The clinical importance of MRD monitoring has been best established in APL, where achievement of molecular remission in the bone marrow (BM) after consolidation treatment is regarded as a therapeutic objective ([@B26]) and a powerful independent predictor of disease relapse ([@B21]). The role of the best time-point for MRD studies is critical in AML, and in particular in APL, both in patients treated with ATRA-chemotherapy and in those treated with arsenic-trioxide/ATRA regimens ([@B32]). As of CBF fusion transcripts (*RUNX1-RUNX1T1* and *CBFB-MYH11)*, some studies have demonstrated the prognostic value of MRD detection and quantification after induction therapy ([@B27], [@B28]), albeit these transcripts can persist in CR in the long-term, without effects on treatment outcome ([@B33]). Moreover, Jourdan et al. ([@B27]), demonstrated that the 3-log MRD CBF fusion transcripts reduction can be used to discriminate high-risk from low-risk patients. Interestingly, Yin et al. ([@B34]), showed that BM and peripheral blood (PB) levels of *RUNX1-RUNX1T1* and *CBFB-MYH11* transcripts after consolidation therapy and during remission were predictive of relapse risk. In this context, PB was shown to be more sensitive and informative as starting material for MRD detection, as compared to BM.

Similar to *PML-RARA, NPM1* mutations, present in founder clones in 40--50% of AML patient with normal karyotype ([@B35]) are stable during the course of the disease, therefore representing an ideal leukemia-specific target for MRD assessment ([@B29], [@B36], [@B37]). Following the first application of specific RT-qPCR assays to evaluate the mutation kinetics ([@B38]), several studies have investigated the clinical implications of *NPM1* monitoring ([@B29], [@B39], [@B40]). In particular, Ivey et al. showed in a large prospective study that detection of persistent molecular MRD after the second chemotherapy cycle has clinical relevance ([@B29]). In fact, detection of *NPM1*-mutated transcripts at this time-point was associated with a significantly higher relapse risk and poorer survival rates, independent of other known prognostic factors ([@B29]).

Based on these findings, the ELN Working Party consensus document on MRD in AML ([@B6]), indicates that molecular assessment for *NPM1* mutations, *RUNX1-RUNX1T1, CBFB-MYH11*, and *PML-RARA* fusion transcripts, should be performed at diagnosis, at least after two cycles of induction/consolidation therapy, and every 3 months, for 24 months after the end of treatment. Monitoring of *NPM1* mutated transcripts may be more informative when performed in PB as compared to BM ([@B29]). As to cost-effectiveness, MRD monitoring after 2 years of follow-up should be decided based on the relapse risk of the specific AML subtype ([@B24]).

Conversely, the reliability of *WT1* expression analysis as MRD marker has remained more controversial, due to the low sensitivity and specificity of the molecular assays, based on arbitrary cut-off levels for *WT1* overexpression in malignant cells, as compared to normal hematopoietic cells ([@B41]). Since kinetics, cut-off values and time-points for *WT1* analysis are controversial, its expression should be evaluated in cases without an identifiable molecular and phenotypical marker, and the validated MRD assay developed by ELN should be adopted ([@B42]).

Next-Generation Sequencing (NGS) {#s3}
================================

Next-Generation Sequencing (NGS) is becoming an important tool for the molecular dissection of AML at the time of initial diagnosis, especially in cytogenetically normal AML, which is characterized by high clonal heterogeneity ([@B43]). Indeed, different clones, characterized by specific mutations or their combinations, may show variable sensitivity to therapy and distinct relapse tendency. NGS is potentially applicable to all leukemic patients, but the interpretation of results requires highly specialized bioinformatic approaches. Main NGS technologies include: (a) Whole Genome Sequencing (WGS), (b) Whole-Exome Sequencing (WES), and (c) Targeted-gene sequencing. In particular, the latter method provides simultaneous profiling of several genes of interest and is clinically applicable to dissect the impact of combined mutations as potential targets for MRD assessment, and as measurable biomarkers of treatment ([@B1], [@B44]). Klco et al. performed WES at the time of diagnosis in 71 AML patients, treated with standard induction chemotherapy, and showed that mutations persisting at day 30 in at least 5% of BM cells were associated with reduced overall survival (OS) and increased risk of relapse ([@B45]). The NGS-based MRD assessment can also identify potentially important changes occurring at the subclonal level during the disease course ([@B36], [@B46], [@B47]).

The persistence of molecular MRD at the time of CR as an independent prognostic factor for survival ([@B48]), was also demonstrated by Jongen-Lavrencic et al. ([@B49]), who analyzed by targeted-NGS 482 AML patients, at diagnosis and in CR after induction therapy. Mutations persisted in about 50% of patients at the time of CR and the presence of most mutations was associated with an increased risk of relapse ([@B50]). However, some of the persisting mutations such as *DNMT3A, ASXL1*, and *TET2* ([@B49]), collectively termed DTA, known to be frequent in clonal hematopoiesis (CHIP) ([@B51], [@B52]), did not have a prognostic role. It is therefore, clear that NGS-based MRD assessment is hampered by the presence of clonal hematopoiesis and ancestral clones. In this context, our group ([@B53]) recently demonstrated that expression levels of *DNMT3A* mutations do not reflect disease status in AML, and that, distinct from *NPM1* mutations, they characterize pre-leukemic populations persisting at the time of CR. Similarly, Debarri et al. ([@B54]) showed that MRD-positivity for *DNMT3A* mutations by NGS did not correlate with increased relapse risk during follow-up. Collectively, these data confirm that DTA mutations are not sufficient *per se* to induce leukemia and do not reflect the presence of a specific disease, but may set the genetic ground for the development of myeloid malignancies, mainly in older patients ([@B55]).

In addition to the role in MRD assessment, the detection of small subclones by NGS is important to evaluate clonal evolution during the disease course. Actually, some of the mutations are not stable and can become detectable or disappear at the time of relapse, due to the emergence of new resistant subclones, as in the case of the *FLT3*-ITD aberration ([@B47], [@B56]--[@B58]). These mutations represent an issue in AML since *FLT3*-ITD-mutated cells, although chemosensitive at diagnosis and responsive to initial chemotherapy, lead to relapse in a substantial number of patients especially those who have not received allo-SCT. Several researchers attempted to develop MRD tools to evaluate *FLT3*-ITD kinetics in AML, but the applicability of this approach was limited because of low sensitivity, and the necessity to design patient-specific assays based on the length of nucleotide inserts ([@B47]). On the other hand, MRD negativity for *FLT3*-ITD mutation is not a reliable disease marker due to the occurrence of *FLT3*-ITD negative relapses in about 25% of patients with a positive test at diagnosis ([@B57], [@B59]). Recently, Levis and co-authors ([@B60]) described the development of a combined PCR/NGS methodology, with high sensitivity and specificity for *FLT3*-ITD-mutated AML. Although validation in clinical trials is necessary, this tool may represent a good NGS-based MRD platform to evaluate clinical responses, and to trace the clonal evolution of *FLT3-*ITD mutations, taking into account possible phenotypic "shifts" during disease evolution.

Newer molecular alterations are currently evaluated as targets for MRD assessment. Kohlmann et al. successfully used amplicon-based NGS to detect and quantify *RUNX1* gene mutations in a cohort of 814 AML patients. *RUNX1*-mutated transcript levels significantly correlated to clinical outcome, and in particular, stratification of patients according to median *RUNX1* mutation levels influenced event-free survival (EFS) and OS ([@B61]). *RUNX1*-MRD longitudinal assessment could be particularly useful to monitor disease progression from myelodysplastic syndromes to secondary AML ([@B9], [@B61], [@B62]).

Conventionally, although NGS-based MRD measurements could be applicable in all AML patients, its current error rates set the sensitivity level at about 1% ([@B63]). Moreover, although several studies underline the potential of NGS to track MRD, technical issues remain to be evaluated. Indeed, many NGS libraries are prepared through multiple rounds of PCR amplification and therefore potential artifacts can be introduced, making it difficult to distinguish these errors from true mutations present at low allele frequency. To overcome this problem, which impairs wide application of NGS, random barcodes or molecular indexes have been introduced in several NGS platforms, to remove errors introduced by PCR amplification, thereby allowing reliable and accurate quantification of genetic targets ([@B63], [@B64]). These molecules, which anneal to specific sequence fragments, may be applied to all NGS-based assays to increase the sensitivity of the detection limits, and to accurately identify low-frequency alleles and copy number variants ([@B65], [@B66]).

Digital Droplet PCR (ddPCR) {#s4}
===========================

In the clinical practice and research, MRD evaluation requires the ability to identify disease related mutations present at very low frequencies. Digital droplet PCR (ddPCR) is a recently introduced molecular assay with great potential for MRD monitoring, due to its high sensitivity and specificity. It is a high-throughput technology that, unlike conventional RT-qPCR, produces an absolute quantification, by amplifying target genes without a reference standard curve ([@B32], [@B67]). Indeed, although RT-qPCR assays are nowadays carefully standardized for accurate molecular quantifications ([@B31]), PCR amplification bias can influence reaction efficiency, leading to imprecise genetic quantification. The ddPCR technique is increasingly applied for the detection of mutations and translocations at high sensitivity, based on patient\'s genetic characteristics. Starting material for ddPCR may be RNA or DNA molecules that are fractionated into thousands of droplets, where each PCR amplification of the target gene occurs. Compared to NGS, ddPCR is characterized by an inferior error rate, is faster and does not require a bioinformatics expert to analyse the results. Despite its high sensitivity (\>10-3), the major pitfall of ddPCR is that a single assay needs to be developed for specific base changes in the same gene.

Among clinically relevant mutations, those affecting *NPM1* are suitable for sensitive ddPCR testing. Actually, *NPM1*-mutated monitoring is sometimes troublesome due to the presence of several frameshift insertions and lack of information on the mutated sequence at diagnosis. In fact, MRD analysis in *NPM1*-mutated patients requires identification of the specific insertion by DNA sequencing to design the appropriate allele-specific RT-qPCR test ([@B38]), and requires commercial plasmid standards for each mutation, currently available only for the three most common mutations. Conversely, ddPCR does not require a standard amplification curve and is highly concordant with RT-qPCR for the detection of rare *NPM1* mutations ([@B68]). A recent study showed that ddPCR can be used to monitor MRD using multiple *NPM1* mutation-specific primers ([@B69]). The multiplex assay has an overall excellent concordance with single mutation-specific ddPCR assays, as well as with conventional RT-qPCR. These data suggest that a single ddPCR can effectively quantify *NPM1* MRD, reducing the potential difficulties associated with *NPM1* quantification, also in patients with unknown or rare mutant sequences.

In addition to *NPM1*, genes involved in the regulation of DNA methylation as *DNMT3A* and *IDH1/2* are recurrently mutated in AML ([@B70]), and have been reported to occur very early during leukemogenesis ([@B71]). These alterations, in particular in the *DNMT3A* gene, are frequently detectable in the peripheral blood of healthy individuals, representing pre-leukemic clones, in the context of CHIP ([@B51]). In AML, Ivey and colleagues ([@B29]), analyzed by ddPCR the kinetics of *DNMT3A* and *IDH* mutations in a large cohort of AML patients, who were in molecular remission for the *NPM1*-mutation. They showed that *DNMT3A* and *IDH* alterations may persist in patients in remission at long-term, confirming that these mutations are not disease-specific and may be eliminated by allo-SCT only. Although the prognostic value of *IDH* mutations is still unclear ([@B72]), Ferret et al. ([@B73]) demonstrated that ddPCR monitoring of *IDH mutations* after allo-SCT, could help to early identify disease persistence and anticipate hematologic relapse. These data have been confirmed by Winters et al. who demonstrated the utility of ddPCR for post-SCT MRD monitoring ([@B74]). Finally, although the prognostic value of conventional RT-qPCR in APL is well-established ([@B75]), Brunetti et al. recently demonstrated that ddPCR may also be used to monitor patients at high-risk of relapse. In APL, we showed that ddPCR may detect mutations associated with arsenic trioxide (ATO) resistance such as the *PML* A216V mutation ([@B76]). We were able to show that this technology could identify mutated cases earlier in the disease course and at very low *PML-RARA* copy number, as compared to conventional sequencing approaches. The identification of the *PML* A216V mutation by ddPCR in APL cases at the time of molecular relapse may in the future help to anticipate treatment decisions in ATO-resistant patients.

Multiparametric Flow-Cytometry (MFC) {#s5}
====================================

The advantages of MFC for MRD assessment include its applicability to virtually all patients (\>90% of AML), the rapidity, and the ability to distinguish viable cells from debris and dead cells ([@B77]--[@B80]). *Furthermore, the technique is considered less labor-intensive with a shorter turnaround time as compared to RT-qPCR* *(*[@B81]*). The availability of instruments equipped with multiple lasers allows the fast implementation of multi-color assays, eventually increasing sensitivity that can be reasonably put between 10*^−3^ *and 10*^−5^.

*The detection of residual leukemic cells by MFC relies on the detection of antigens and/or physical abnormalities that are absent or infrequent in normal BM. Such aberrancies are mainly represented by cross-lineage expression, overexpression, reduced, absent, and asynchronous antigens expression and are defined as leukemia associated immunophenotypes or LAIPs*. A complementary technique of analysis is represented by the "different from normal" (DfN) approach. In this approach, a standardized combination of antibodies is applied to all MRD analyses, regardless of LAIP, allowing the identification of events outside the maturation patterns of normal BM. The harmonization of these analytical strategies has been endorsed by the ELN group ([@B24]) and may overcome the concerns on immunophenotypical shifts, that make MRD a moving target in AML ([@B82]). The application of panels including at least eight colors and the acquisition of a proper number of events minimizes the possibility to miss minor populations present at diagnosis that may eventually generate relapse ([@B24]). The panel of the ELN MRD working party suggests that to achieve a reliable estimation with a threshold set at 0.1%, the amount of residual leukemic cells by MFC should be determined on a denominator of at least 0.5-1 × 10^6^ cells, excluding debris and CD45 negative cells ([@B23], [@B24]).

Nevertheless, the major drawback of MFC-MRD is that it has been defined by few laboratories with a specific and robust expertise ([@B23], [@B37]). This is related in part to differences in specificity of the different LAIPs/DfNs used in clinical practice, which require high levels of expression for the identification of AML-specific events ([@B80]).

The value of MRD by MFC has been retrospectively validated as a biomarker of mCR quality with a remarkable impact on DFS, OS, and cumulative incidence of relapse (CIR) ([@B37]). Few published studies have addressed this issue prospectively. *In the pediatric protocol AML02, risk-categories were discriminated relying on the upfront genetic/cytogenetic profile and on the level of FCM-MRD after the first cycle of chemotherapy. Treatment was intensified by gemtuzumab ozogamicin in patients with high levels of MRD. The study came out with a superior clinical outcome as compared to previous not risk-adapted trials of the same institution* *(*[@B83], [@B84]*). In the GIMEMA adult AML1310 trial, patients with intermediate-risk AML (intermediate karyotype or FLT3-TKD positive or c-kit mutated CBF-positive) received autologous-SCT or allo-SCT depending on the level of FCM-MRD, considering a threshold of 0.035%. OS and disease-free survival (DFS) at 24 months were superimposable (78.6 and 61.4% in MRD-positive and 69.8 and 66.6% in MRD-negative patients). These results suggest that whereas in intermediate risk patients, allo-SCT can be avoided if MRD is not detectable, in MRD positive ones allo-SCT can actually prolong OS and DFS up to those of the MRD-negative category* *(*[@B85]*)*.

The occurrence of relapse in a proportion of patients achieving a MRD-negative status, roughly ranging between 20 and 25%, still represents a major drawback of all MRD studies ([@B86]). This evidence, despite MRD negativity, refines the relapse risk much better than mCR, and still limits its large-scale use in the decision-making process of AML treatment. The possible explanations of this inaccuracy may reside both on technical and biological reasons. In fact, poor quality of BM samples and contamination of peripheral blood and/or immature populations in the regenerative post-chemotherapy phase may hamper the specificity of immunophenotypic combinations adopted to track MRD. *A further explanation may be the presence of minority populations undetectable with current phenotypical approaches (e.g., leukemic stem cells, LSC) that may survive chemotherapy and eventually lead to relapse* *(*[@B84], [@B87]*). Both normal stem cells and LSC reside in the CD34*+*/CD38-- cells and MFC can distinguish LSC by applying a multicolor analysis including a specific set of markers* *(*[@B88]--[@B91]*). When the presence of LSC, at diagnosis or during the treatment course, was determined and compared with MRD the presence of LSC represented a further negative prognosticator both in MRD-positive and, remarkably, in the MRD-negative populations of patients. This observation was confirmed both in a retrospective study, and prospectively in the context of HOVON/SAKK 102 study* *(*[@B89], [@B92]*). Accordingly, ELN guidelines suggest the inclusion of MFC determination of residual LSC during treatment of AML, suggesting that a dedicated test tube should be developed to this purpose* *(*[@B24], [@B84]*)*.

*Possible future developments in MRD detection by MFC will be accomplished by the use of high-throughput methods, e.g., next-generation flow cytometry (NGF)* *(*[@B84]*). The potential advantage of these techniques is that they can process huge amounts of immunophenotypically stained cell (*\>*10*^7^ *cells) in parallel, substantially increasing the level of sensitivity of the conventional 8--10-color MFC assays. Due to their technical features, these techniques may be prospectively repeated along the treatment course, providing an estimate of clonal evolution of the disease. This may prove useful in AML, whose over time intra-clonal variability may hamper the possibility of a real-time estimation of disease plasticity. NGF has been reported to show significant utility in the monitoring of tumor burden in the setting of multiple myeloma* *(*[@B93]*)* *and acute lymphoblastic leukemia* *(*[@B94]*), suggesting that similar approaches may be exploited in AML*.

Another promising technique in leukemia diagnostics is mass-cytometry time-of-flight (CyTOF). In CyTOF, antibodies are labeled with transition elements instead of fluorochromes, allowing up to 130 different parameters to be combined in the evaluation of a single cell. Furthermore, since rare elements are absent in biological systems, this approach virtually eliminates the background noise, which commonly affects MFC assays ([@B95]). Nowadays, although continuous instrument development and the need of complex analytical tools (e.g., SPADE or ViSNE) still limit the wide application of CyTOF to MRD detection on a routine basis, the multiparametricity of this technique may represent the ideal approach to empower our understanding of the heterogeneity of AML also in MRD studies.

Conclusions {#s6}
===========

Minimal Residual Disease (MRD) detection has strong clinical relevance in AML and new technological advances have increased its sensitivity and specificity, making it an essential tool in the overall strategy adopted to treat AML. However, different methods have specific indications and require highly specialized expertises ([Table 1](#T1){ref-type="table"}). Whatever method is indicated in specific situations, especially in the routine clinical care, it is mandatory to use standardized techniques, apply rigorous bioinformatic analyses and define specific time-points, developed in the context of laboratory networks, which can ensure interlaboratory reproducibility. Several techniques may be needed, but the results should be integrated in a final laboratory report, which covers the different methodologies and maximizes clinically useful information, with the final goal of better addressing personalized treatment approaches.

###### 

Applications and potential pitfalls of MRD testing in AML.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Type of leukemia**                       **Marker**        **Method**   **Sensitivity**    **Source**                      **Applicability**        **Optimal time point**                                     **Advantages**                             **Pitfalls**
  ------------------------------------------ ----------------- ------------ ------------------ ------------------------------- ------------------------ ---------------------------------------------------------- ------------------------------------------ -----------------------------------------------------
  AML with recurrent genetic abnormalities   *PML-RARA*        RT-qPCR      10^−5^ to 10^−6^   B                               Specific AML subgroups   \- After two cycles of standard induction/consolidation\   -High stability\                           Stable, molecular relapse is a treatment indication
                                                                                                                                                        -After the end of treatment\                               -Specific\                                 
                                                                                                                                                        -Every 3 months for 24 months after end of treatment       -Low background in normal cells            

                                             *NPM1*-mut                                        PB and/or BM every 4--6 weeks                                                                                                                                  

                                             *CBFB-MYH11*                                                                                                                                                                                                     Present in pts in CCR. Transcript kinetics useful

                                             *RUNX1-RUNX1T1*                                                                                                                                                                                                  

  Other AML                                  *DNMT3A*-mut      ddPCR        10^−3^             BM                                                       To be defined                                              Unreliable markers, associated with CHIP   

                                             *IDH1/IDH2*-mut                                                                                                                                                                                                  

                                             *WT1*             RT-qPCR      10^−5^ to 10^−6^   PB                                                       \- After standard induction                                -Suggested in pts without a MRD-marker.    -Low sensitivity and specificity\
                                                                                                                                                                                                                                                              -Expressed by normal cells

                                             LAIP              MPFC         10^−4^ to 10^−5^   BM                              Wide (\>90%)             \- After the 2 cycle                                       -Fast, cost-effective\                     -Subclone expansion\
                                                                                                                                                                                                                   -Single cell analysis                      -Phenotypic shifts\
                                                                                                                                                                                                                                                              -Complex analysis
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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